Sublime

Emerging therapeutics for strategic acquirers – What do biopharmas already have and may need? From RBC https://t.co/RXao1AnGT8

$NAVB has been approached as an acquiring target. They’ve been attracting investors and biotech companies’ attentions. You never know when you would get another jackpot just like $SGTX. 👇👇 https://t.co/gCdfGF6RG8

美债产品分类（转自雪球） https://t.co/CTmQ5PRkcR